Non-small cell lung cancer

News

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappo

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

News

Imfinzi fails lung cancer trial, but scores in bladder cance...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladde

News

ASCO: KRAS upstarts set their sights on NSCLC market

There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them.

News

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress.

News

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

Imfinzi fails lung cancer trial, but scores in bladder cance...

ASCO: KRAS upstarts set their sights on NSCLC market

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks